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ABSTRACT 
Lung immaturity remains a major cause of morbidity and mortality in extremely 
premature infants. Positive-pressure mechanical ventilation, the method of choice for 
respiratory support in premature infants, frequently promotes by itself lung injury and a 
negative impact in the circulatory function. Extracorporeal lung support has been 
proposed for more than 50 years as a potential alternative to mechanical ventilation in 
the treatment of severe respiratory failure of extremely premature infants. Recent 
advances in this field included the development of miniaturized centrifugal pumps and 
polymethylpentene oxygenators, as well as the successful use of pump-assisted veno-
venous extracorporeal gas exchange systems in experimental artificial placenta models. 
This review, which includes studies published from 1958 to 2015, presents an update on 
the artificial placenta concept and its potential clinical applications. Special focus will 
be devoted to the milestones achieved so far and to the limitations that must be 
overcome before its clinical application. Notwithstanding, the artificial placenta stands 
as a promising alternative to mechanical ventilation in extremely premature infants. 
 
Keywords: Artificial placenta; bronchopulmonary dysplasia; extracorporeal membrane 
oxygenation; extremely premature infant; respiratory distress syndrome. 
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INTRODUCTION 
According to the World Health Organization, 15 million premature infants are 
born every year, with almost 1 million deaths directly attributed to prematurity1. 
Although all premature infants are at risk for complications, extremely premature (EPT) 
infants, born at or before 28 weeks of gestation, suffer the greatest morbidity and 
mortality1. Respiratory distress syndrome and bronchopulmonary dysplasia remain a 
major cause of morbidity and mortality in EPT infants2. This relates with pulmonary 
immaturity, given that EPT infants are born during the canalicular period of lung 
development, characterized by capillarization and pulmonary acini morphogenesis, with 
insufficient surfactant production3. 
Positive-pressure mechanical ventilation with high oxygen concentrations 
remains the method of choice to provide lung support in preterm infants with severe 
respiratory failure4. However, mechanical ventilation in preterm infants promotes, by 
itself, lung injury that negatively impacts survival. The known direct mechanisms of 
ventilator-induced lung injury are barotrauma, volutrauma and atelectrauma5. These 
mechanisms promote biotrauma with capillary endothelium, alveolar epithelium, and 
basal membrane damage, which results in fluid, protein and blood extravasation into the 
airways, alveoli, and pulmonary interstitium, with consequent surfactant inhibition and 
activation of local and systemic inflammatory responses6. Mechanical ventilation also 
adversely affects the circulatory function of preterm infants, reducing pulmonary blood 
flow and left ventricular output7,8. In fact, positive-pressure mechanical ventilation 
decreases the alveolar/capillary transmural pressure gradient, causing compression of 
the intra-alveolar capillaries, which increases pulmonary vascular resistance, therefore 
decreasing pulmonary blood flow9. Further increases in airway pressure and pulmonary 
vascular resistance may sustain pulmonary arterial pressures above systemic arterial 
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pressures, potentiating continued right-to-left shunt through the ductus arteriosus. The 
effect of positive-pressure ventilation is not limited to the pulmonary vasculature, with 
direct compressive effects observed on the newborn heart, resulting in reduced cardiac 
performance and ventricular output10. This could be particularly relevant in the 
immature myocardium of the preterm heart that presents low contractility with an 
inability to cope with increasing afterload in the days after birth11. 
In light of these limitations, extracorporeal lung support has been proposed more 
than 50 years ago as a potential alternative to mechanical ventilation in the treatment of 
severe respiratory failure of EPT infants12. Its main benefits reside in the fact that, by 
bypassing the lungs completely, the AP avoids potential barotrauma resulting from 
mechanical ventilation. However, by then, artificial organ technology was still in its 
infancy and the understanding of EPT pathophysiology was very limited. More recently, 
important developments in extracorporeal lung assist technology were observed, 
fostering a renewed interest in artificial placenta (AP) research.  
In this review, an update on the AP concept and its potential applications is 
presented. Special focus will be devoted to the milestones achieved so far and to the 
major limitations that must be overcome before its clinical application. 
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METHODS 
Eligible studies were identified by an electronic search of PubMed and Scopus, 
involving studies published from 1958 to 2015. The sensitive search strategy combined 
the following keywords: artificial placenta; bronchopulmonary dysplasia; 
extracorporeal lung assist; extracorporeal membrane oxygenation; extremely 
premature infants; polymethylpentene oxygenator; and respiratory distress syndrome. 
All articles and cross-referenced studies from retrieved articles were screened for 
pertinent information and reviewed by both Authors. 
Inclusion criteria consisted in experimental and systematic review articles, 
published as original studies, with available abstract. Publications not written in English 
or not related to the neonatal period were excluded. 
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ARTIFICIAL PLACENTA: THE CONCEPT 
The terminology describing extracorporeal life support (ECLS) in premature 
infants is divided in three categories, established according to the gestational age13: i) 
neonatal ECMO: for infants of at least 34 weeks of gestation (moderate to late preterm 
newborns1); this technique is successfully used in clinical practice for more than 30 
years; ii) preemie ECMO: for premature infants between 29 and 33 weeks of gestation 
(very preterm newborns); although technically feasible, reduced survival and increased 
rates of intra-ventricular hemorrhage have been reported14; and iii) artificial placenta: 
for EPT infants, born before 28 weeks; the AP currently remains under experimental 
research. 
Therefore, the AP concept consists in extracorporeal membrane gas exchange 
(blood oxygenation and extracorporeal CO2 removal) for EPT infants with immature 
pulmonary system and severe respiratory failure, as a bridge to the development of 
native lung function8. The AP does not include provision of other placental functions 
such as nutrient or metabolic product exchange. 
AP models are generally defined by the following characteristics 8,13,15,16: i) 
extracorporeal lung support with preservation of fetal circulation: either the umbilical 
artery (pumpless arterio-venous ECLS, AV-ECLS) or a central vein (pump-assisted 
veno-venous ECLS, VV-ECLS) are used for blood outflow from the patient to the 
extracorporeal circuit; the umbilical vein is always used for inflow to the patient from 
the extracorporeal circuit17 (Fig. 1); ii) low partial pressure of oxygen, given that 
oxygen-binding capacity of fetal hemoglobin and hematocrit are increased; iii) absence 
of positive-pressure mechanical ventilation; iv) simulated fetal breathing with fluid-
filled lungs; v) biocompatibility of the extracorporeal circuit inner surfaces in direct 
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contact with blood; high levels of systemic anticoagulation associated with an 
unacceptable risk of intracranial hemorrhage in EPT infants18. 
 Pump-assisted VV-ECLS systems presents several advantages when compared 
to pumpless AV-ECLS17: i) arterial vessel cannulation is not required; cannulation of 
umbilical arteries in EPT infants is technically challenging and frequently complicates 
with vessel spasm; ii) an external blood reservoir is not required given that the EPT 
infant’s own venous system is used as blood reservoir; iii) it operates in parallel with 
systemic circulation, therefore not increasing afterload of the fetal heart; differently, 
pumpless AV-ECLS operates in series with systemic circulation, increasing the fetal 
heart workload that can complicate with high-output heart failure. 
Membrane lung permeability to O2 and CO2 is a critical factor influencing AP 
performance. Silicone rubber membranes were initially used, composed of a permeable 
non-porous polymeric material with loosely packed polymeric chains19. Another type of 
oxygenator is the hollow-fiber membrane, which has woven capillary tubes composed 
of microporous polypropylene20. Despite higher gas permeability, polypropylene 
membranes are less frequently used given the high plasma leakage risk with increased 
extracorporeal circuit blood pressures20. Moreover, silicone rubber membranes present 
higher biocompatibility when compared with polypropylene fibers for long-term 
ECLS21.  
Polymethylpentene (PMP) oxygenators have been used in clinical practice for a 
decade22. PMP fibers have an asymmetric pore structure with a very thin dense outer 
skin that allows gas transference while suppressing the direct contact of blood and gas 
across micropores23. These features enhance durability and greatly reduce plasma 
leakage23. Moreover, PMP oxygenators present more efficient priming, reduced 
hemodynamic resistance and better preservation of coagulation proteins21.  
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EARLY MILESTONES 
Following the development and implementation of the heart-lung machine, it 
was soon recognized that this concept could be similarly applied to the treatment of 
severe respiratory failure of the premature infant24. In 1958, Westin et al. prolonged the 
life of previable human fetuses by cannulating the umbilical vessels and circulating the 
fetal blood through a rotating oxygenator25. When injecting regular doses of glucose 
solution, the fetal heart continued to beat for a period up to 12 hours25. The fetuses were 
maintained in a warm artificial amniotic fluid bath25. 
Callaghan et al. were the first to develop the AP concept in animal experiments, 
back in 1961. A pump-assisted VV-ECLS circuit with a rotating disc oxygenator was 
used in eight sheep26. Blood outflow from the animal to the extracorporeal circuit was 
performed via both femoral and jugular veins, while inflow to the animal from the 
extracorporeal circuit was made either through the right atrium or the right ventricle26. 
In 1962, a period of up to 2.5 hours survival of mongrel dogs using this procedure was 
reported27. 
These achievements have been overcome by Lawn and McCance28, who 
conceived a pumpless AV-ECLS circuit with a dialyzer that was tested in previable pig 
fetuses. Blood drained from the umbilical arteries circulated through the oxygenator and 
then through cellophane tubing immersed in a suitable rinse. Blood returned to the 
umbilical vein without requiring external pump assistance28. A similar perfusion 
apparatus was constructed in 1964 by Alexander et al., but the dialyzer was excluded29. 
It was concluded from their experiments that a perfusion system with constant volume 
would be necessary, due to changes in venous pressure29.  
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Meanwhile, SenGupta et al. described a portable, self-contained and self-
powered AP consisting of a flexible, inert silicone elastomer membrane oxygenator and 
a pump30. Their first experiment had eleven out of sixteen survivors during up to 5 
hours of connection to the AP30. Two years later, there were sixteen survivors out of 
twenty dogs, and most perfusions took more than 2 hours. Though satisfactory 
oxygenation was obtained, the short period of survival was considered unsafe31. 
Significant progress was achieved in 1969 by Zapol et al.32, when a premature 
lamb fetus was totally sustained by extracorporeal perfusion using a silicone-membrane 
blood oxygenator32. The animal received parenteral nutritional support and remained 
metabolically stable for up to 55 hours. A study with ten lamb fetuses using 
angiocardiographic techniques was presented the following year33. Zapol et al. also 
described the modulation of ductus arteriosus and pulmonary blood flow by blood 
oxygen tension in their AP model34. 
Efforts on the development of an AP were almost entirely abandoned by 1979, 
when a completely different approach to treat severe respiratory failure in premature 
infants was implemented: positive-pressure mechanical ventilation35,36. This led to a 
dramatic improvement of premature infants’ survival, although many problems 
remained37. Compared with positive-pressure mechanical ventilation, the AP was at that 
time too complex and unsafe for clinical use leading to a gap of research in the next 
decade. 
In 1987, Kuwabara et al.38 developed a novel AP system. They compared two 
types of circuits, with and without a blood reservoir, using goat fetuses. In the first 
group, the duration of incubation was increased to 165 hours, in contrast to the 8 hours 
achieved by the control group38. The oxygenator was made of silicone, and blood was 
drained from the umbilical arteries and returned to the umbilical vein38. This was the 
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first report on animal experiments of successful long-term (up to 7 days) AP support. 
Several improvements were made to this novel AP system, including alterations in fetal 
catheterization and addition of a dialyzing system to the extracorporeal circuit, which 
allowed the survival of goat fetuses up to 236 hours39.  
In 1993, continuing this work, Unno et al. tried a new protocol to study the 
influence of body movement on goat fetuses’ survival40. It was demonstrated that AV-
ECLS with umbilical blood access could support premature goat fetuses for up to 3 
weeks40. The following studies focused on fetal hemodynamics, such as goat fetal 
ductal blood velocity through Doppler echocardiography41 and the effect of 
prostaglandin E142. This last experiment suggested that the administration of 
prostaglandin E1 prevented the constriction of ductus arteriosus, a phenomenon that 
was found to disturb fetal circulation to the AP43. This research group also compared 
four different methods to control blood flow in an AV-ECLS circuit, concluding that the 
control of extracorporeal circulation flow by altering the circuit resistance was one of 
the main contributing factors to the success of long-term incubation44.  
In 1998, Sakata et al. reported the successful use of a centrifugal pump, which 
allowed higher extracorporeal flow rates45. This group used polyolefin hollow fiber 
membrane oxygenators, which contributed to low circuit resistance45. In the same year, 
Yasufuku et al. refined the AP concept by performing upper tracheal ligation, which 
maintained lung expansion and protected from meconium aspiration46,47.  
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RECENT MILESTONES 
In 2012 Gray et al.48, from the University of Michigan ECLS Laboratory, 
hypothesized that a pump-assisted VV-ECLS circuit would preserve systemic fetal 
circulation while providing adequate extracorporeal gas exchange48. The right jugular 
vein was cannulated for outflow from the animal to the extracorporeal circuit, whereas 
an umbilical vein was used for blood inflow to the animal from the extracorporeal 
circuit48. Blood cavitation was reduced, since blood was passively drained from the 
right atrium48. A miniaturized polypropylene hollow fiber oxygenator was used. The 
experiment was successful, being the first report of a 24-hour survival of five lamb 
fetuses using a pump-assisted VV-ECLS circuit. Continuing this work, seven lambs 
were incubated on a dry heated waterbed and maintained on VV-ECLS for up to 70 
hours49. This AP model was able to provide hemodynamic stability and efficient 
extracorporeal gas exchange, with preservation of cerebral perfusion for an extended 
period of time49. No signs of gross or microscopic intra-ventricular hemorrhage were 
found despite systemic anticoagulation with heparin49. 
In 2015, Bryner et al. compared a pump-assisted VV-ECLS system with 
positive-pressure mechanical ventilation in EPT lamb fetuses16. Four lambs were 
successfully supported for 1 week using a polypropylene oxygenator and a rotary 
pump16. Differently, lambs treated with positive-pressure mechanical ventilation 
survived on average less than 4 hours, despite the use of exogenous surfactant and 
steroids16. No evidence of intracranial hemorrhage was observed. The main issues faced 
by researchers were directly related to cannulation, with one case of pericardial 
tamponade and arrhythmias16.  
Besides the improvements in extracorporeal circuit configuration, important 
advances were achieved in oxygenator technology. Arens et al.50 developed a 
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miniaturized oxygenator to be used in AP models. This research group catheterized 
lambs through two umbilical arteries and two umbilical veins, and the fetuses were kept 
in a warming bed. Their oxygenator, NeonatOx, was placed as close as possible to the 
lambs, allowing short tubing and low circuit resistance50. Furthermore, the oxygenator 
was miniaturized to a priming volume of only 20 ml. This reduced device surface area, 
decreasing thrombogenesis and inflammation50. NeonatOx allowed successful 
extracorporeal gas exchange for 6 hours in six out of seven animals51. One limitation 
related to the durability of umbilical vascular accesses, since artificial amniotic medium 
submersion was not performed 51.  
Meanwhile, Canadian investigators designed a microfluidic oxygenator with 
efficient gas exchange20. Four different gas permeable membranes were tested using 
human blood. The porous polydimethylsiloxane membrane had the highest gas 
exchange rate20. Recently, further improvements were performed to this oxygenator52, 
with the novel device being modifiable according to the EPT infants’ body weight. This 
microfluidic oxygenator was tested in piglets during 4 hours52. 
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FUTURE DIRECTIONS 
Although much progress has been made in the AP field and despite the different 
models studied so far (Table 1 and Table 2), several limitations still preclude its clinical 
application. 
Regarding the extracorporeal circuit itself, pump-assisted VV-ECLS models 
have shown many advantages over pumpless AV-ECLS circuits. Although its simplicity 
is appealing, the use of pumpless AV-ECLS in EPT infants seems technically 
impracticable due to the small size and tortuosity of the umbilical arteries, as well as to 
the need of prolonged extracorporeal lung support and hemodynamic stability. 
Concerning anticoagulation, the development of novel biomaterials will 
presumably improve surface biocompatibility of the extracorporeal circuit, reducing (or 
even eliminating) the need for systemic anticoagulation, importantly decreasing 
intracranial hemorrhage risk18. In this regard, research is underway towards the 
development of non-thrombogenic surface extracorporeal circuit coating53,54. 
Artificial placenta miniaturization will also be improved, decreasing 
extracorporeal surface area and circuit resistance51. The use of PMP oxygenators, which 
present high durability and reduced plasma leakage, is a predictable next step, given its 
successful use in adult ECMO 23. 
Further studies are required to show that the lung is protected and continues to 
mature during AP support. This implies that lung development between the stages of 
birth, AP support and progression to air breathing needs to be demonstrated and 
documented. 
Concerning the brain, studies need to show that there is adequate brain perfusion 
and that this organ is protected without bleeding or white matter injury during AP 
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support. This is essential given that, regarding neurological complications, the majority 
of sequelae appear to be related to hypoxemia and hemodynamic instability that occurs 
before the onset of ECLS55. 
The impact of the AP in the cardiovascular, gastrointestinal and renal systems 
also deserves further investigation. Cardiovascular stability during pump-assisted VV-
ECLS in EPT infants also needs to be confirmed, before establishing this configuration 
as the preferred AP circuit.  
The ability of EPT infants to wean from AP support without major lung sequelae 
is a central issue that needs further demonstration. This will impact on clinical criteria 
for AP use, which remain to be established.   
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CONCLUSION 
Lung immaturity still associates with high morbidity and mortality in EPT 
infants. Extracorporeal lung support has been proposed for more than 50 years as a 
potential treatment of severe respiratory failure of EPT infants. Recent progresses in 
extracorporeal circuit biotechnology renewed the interest in experimental and clinical 
AP research. Notwithstanding the several challenges remaining, the AP remains an 
attractive potential alternative for EPT infants failing positive-pressure mechanical 
ventilation. The successful application of the AP into clinical practice would definitely 
be a milestone in neonatal medicine. 
56 
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FIGURE 1 
 
 
 
FIGURE LEGEND 
Figure 1. Artificial placenta circuit configurations. (A) Pumpless arterio-venous 
extracorporeal lung support (AV-ECLS): blood inflow to the extracorporeal circuit is 
performed by cannulation of umbilical arteries; the oxygenated blood is then returned to 
EPT infant through the umbilical vein. (B) Pump-assisted veno-venous extracorporeal 
lung support (VV-ECLS): blood is drained from central vein(s) (e.g. internal jugular 
vein); the oxygenated blood is then returned to EPT infant through the umbilical vein. 
 
 
TABLE 1 - Overview of early experiments performed with several AP models 
Reference Year Model Circuit Oxygenator Pump Submersion Survival 
        
25 1958 Human AV-ECLS Rotating film Yes Yes 5-12 hours 
26 1961 Lamb VV-ECLS Rotating disc Yes Yes 8-19 hours 
27 1962 Dog VV-ECLS Rotating disc Yes Yes 2.5 hours 
28 1962 Piglet AV-ECLS Rotating disc film Yes Yes 8 hours 
56 1963 Lamb AV-ECLS Rotating disc film Yes Yes 40 minutes 
29 1964 Lamb AV-ECLS Rotating disc film Yes No 1 hour 
30 1964 Dog AV-ECLS Membrane Yes - 2-5 hours 
12 1965 Lamb AV-ECLS Rotating disc film No Yes 0.3-3 hours 
57 1968 Human - Coiled membrane Yes - 1.5-5 hours 
58 1968 Lamb AV-ECLS Rotating disc film Yes Yes 24 hours 
32 1969 Lamb AV-ECLS Silicone coiled Yes Yes 4-55 hours 
 
 
TABLE 1 (continued) 
 
Reference Year Model Circuit Oxygenator Pump Submersion Survival 
        
59 1979 Lamb AV-ECLS Microchannel membrane Yes No - 
38 1987 Goat AV-ECLS Silicone hollow fiber Yes Yes Up to 165 hours 
39 1989 Goat AV-ECLS Silicone hollow fiber Yes Yes Up to 236 hours 
40 1993 Goat AV-ECLS Silicone hollow fiber Yes Yes Up to 542 hours  
46 1998 Goat AV-ECLS Polyolefin hollow fiber Yes Yes Up to 237 hours 
TABLE 2 - Overview of recent experiments performed with several AP models 
 
Reference Year Model Circuit Oxygenator Pump Submersion Survival 
        
60 2009 Lamb AV-ECLS Hollow fiber No No 4 hours 
50 2011 Lamb AV-ECLS Polypropylene  No No 3 hours 
61 2012 Lamb AV-ECLS Membrane No Yes Up to 30 hours 
48 2012 Lamb VV-ECLS Polypropylene  Yes Yes 24 hours 
49 2013 Lamb VV-ECLS Polypropylene  Yes No 70 hours 
52 2014 Piglet AV-ECLS Microfluidic  No No 4 hours 
51 2014 Lamb AV-ECLS Polypropylene  No No 6 hours 
16 2015 Lamb VV-ECLS Polypropylene  Yes No Up to 1 week 
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2018 UPDATE ON “ARTIFICIAL PLACENTA: RECENT ADVANCES AND 
POTENTIAL CLINICAL APPLICATIONS” 
In 2016, Miura and colleagues modified membranous oxygenators to test the 
hypothesis of a parallelized AP circuit1, and compared it with the single-circuit AP. 
Parallelization of the AP system successfully decreased its resistance and prolonged low-
weight lamb fetuses’ survival up to 64 hours. Moreover, significantly low blood lactate 
levels were registered1. Further studies under a parallelized circuit were conducted, with 
lamb fetuses being kept in a physiologically stable condition for periods of 48 hours2 and 
1 week3. However, white-matter injury was reported in two out of five animals, in each 
experiment1,2. 
Aiming the study of cerebral perfusion and oxygenation, researchers from 
Michigan University ECLS Laboratory successfully maintained fourteen lambs under 
venovenous AP support for up to 92 hours4. Despite the fact that this particular circuit 
configuration presents high risk for cerebral hypoperfusion, spectroscopy and carotid 
arterial flow suggested that brain oxygen delivery was preserved4 and that it poorly 
correlated with systemic oxygen saturation4. Further studies are necessary to assess white 
matter injury, and address the issue of intraventricular hemorrhage, even though necropsy 
evaluations showed no evidence of intracranial hemorrhage in their study4. 
This group of researchers recently concluded that intratracheal perfluorocarbon 
instillation during AP support prevents lung injury and maximizes lung development, in 
comparison with the previously preferred approach with amniotic fluid and tracheal 
occlusion5. Increased surfactant production was also reported5. With further development, 
the VV-ECLS may offer a feasible alternative for EPT infants. 
2 
 
In 2017, Flake and colleagues presented a unique AP system that incorporates a 
pumpless oxygenator through an umbilical vascular interface kept within a closed fluid 
circuit, the polyethylene Biobag6. This model, which resembles the womb environment 
in shape and size, allowed eight fetal lambs to grow in a temperature-controlled, near-
sterile environment, breathing an amniotic-like fluid6. Swallowing an electrolyte solution 
improved fetal fluid homeostasis and provided an additional route for nutrition. 
Furthermore, since there was continuous fluid exchange, this configuration solved the 
problem of gross fluid contamination and infection6. 
In this study, double umbilical artery and single umbilical vein cannulation were 
preferred over carotid use, preserving a length of native umbilical cord between the 
cannula tips and the abdominal wall. This approach allowed vascular adaptation to 
pressure changes across the AV shunt7 and was proven to optimize circuit flow dynamics 
and stability, since it closely relates to the placental physiology in comparison to other 
cannulation methods7. 
Remarkably, Flake et al. reported successful transition to air breathing after AP 
support in two lambs that were connected to the circuit for 21 and 29 days, respectively8. 
The animals presented satisfying responses to feeding and normal somatic growth8. One 
did not survive a pyelonephritis after 12 days of independent life, whereas the other 
reportedly surpassed three months survival with apparently normal neurological 
outcomes8. 
These results are historical and superior to all previous attempts of EPT lambs’ 
ECLS in both duration and physiologic well-being. Researchers will carry on evaluating 
and refining this AP system, since it needs to be downsized for human infants, who are 
one-third the size of the experimental fetus lambs. The first clinical trial is expected to 
occur within five years.   
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Editorial
The Artificial Placenta: Is Clinical Translation Next?
George B. Mychaliska, MD*
Despite significant advances in the treatment of
prematurity including antenatal steroids, advanced me-
chanical ventilation strategies, and exogenous surfactant,
the mortality and morbidity remain high for these
vulnerable infants. In particular, the mortality and
morbidity of extremely low gestational age newborns
(ELGANs) defined as <28 weeks estimated gestational
age (EGA), is extremely high.1 A radical paradigm shift in
the treatment of extreme prematurity would be to re-
create the intra-uterine environment using an extracorpo-
real artificial placenta (AP).
In this issue,Metelo-Coimbra andRoncon-Albuquerque2
review recent advances in the field and assess barriers to
clinical translation. From the outset, it should be acknowl-
edged that although there is a large number of premature
births worldwide (defined as <37 weeks EGA), outcomes
have substantially improved for infants >28 weeks EGA.
Apart from some specific congenital anomalies like
congenital diaphragmatic hernia, the AP is intended
for the treatment of ELGANS who experience the
most complications of prematurity and whose outcome
remains poor.
The authors focus on lung immaturity and provide
substantial evidence of the iatrogenic effects of mechani-
cal ventilation on both lung injury and the deleterious
cardiovascular effects.2 It is worth noting that although
ELGANS are predisposed to interventricular hemorrhage
(IVH) given their immature germinal matrix, mechanical
ventilation has been implicated in the pathogenesis of
IVH by increasing intrathoracic and intracranial pressure
with every breath.3 The ELGANswho are never subjected
to positive airway pressure have fewer complications of
prematurity. An appreciation of the deleterious effects of
mechanical ventilation and high oxygen concentrations
on premature lungs has led to a dramatic shift toward less
invasive ventilator strategies for premature infants.
Although this strategy appears promising for some
patients,4 there is still a subset of ELGANS that cannot
maintain adequate gas exchange with the most invasive
ventilator strategies.
Although the pulmonary system is critical to initial
survival and long-term pulmonary morbidity is high
among survivors, there are other significant complications
of ELGANs that warrant consideration. Predictable and
unsolved complications associated with prematurity
include neurologic injury (IVH, white matter injury),
necrotizing enterocolitis (NEC), retinopathy of prematu-
rity (ROP), and sepsis. Our current inability to prevent
these complications relates both to organ immaturity and
conventional treatment strategies such as positive
pressure ventilation, that have historically been developed
for full term infants. To potentially solve these problems,
the AP must not only recreate the fetal milieu and provide
life-sustaining functions such as adequate gas exchange
and fetal hemodynamic stability, but it should also protect
against organ trauma and allow the normal developmental
pathways to occur.
An AP may appear far beyond the reach of modern
science, but the idea of creating a life support system to
maintain growing fetuses in a womb-like environment
with extracorporeal support was first investigated 60 years
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ago! Metelo-Coimbra and Roncon-Albuquerque provide
a succinct review of AP terminology and history of
milestones.2 Since fetuses normally develop with extra-
corporeal support, it should perhaps not surprise us that
researchers were drawn to this concept shortly after the
successful introduction of cardio-pulmonary bypass. For
historians of science, it is noteworthy that researchers
were on the right path, but got derailed many times due to
the state of biomedical technology and insufficient
knowledge of the physiology of premature infants. In
my view, the history of the development of the AP is
marked by many experimental failures with episodic
successes. Despite incremental success, many research
groups abandoned this work as progress was being made
with antenatal steroids, exogenous surfactant, advanced
mechanical ventilation strategies, and ECMO for term
and near-term infants.
An appreciation of the unsolved problems of extreme
prematurity coupled with recent advances detailed by the
authors2 has led to a resurgence of work on theAP. The fetal
lamb is the best model, and the lamb gestational age which
corresponds to ELGAN lungs is 118 days gestation
(term¼ 145 days). Although the AP is promising and has
the potential to radically change the treatment of
prematurity, several obstacles remain. As the authors point
out,2 the first issue is themost effective ECLS configuration.
A simple pumpless AV-ECLS circuit utilizing the umbilical
vessels is appealing, but our experience demonstrated only
short-term survival and declining cardiac function.5 Despite
cannulation of the umbilical arteries to the sheep aorta (to
obviate vessel spasm) and adding a pump, matching
extracorporeal flow to systemic flow is very difficult (the
native placenta does this automatically). In addition, given
the tortuosity, size, and spasm associated with human
umbilical arteries, we transitioned to a pump-driven VV-
ECLSmodel with inflow via the umbilical vein and outflow
via the jugular vein. This approach provides 7 days of
support with excellent gas exchange and hemodynamic
stability.6 With current technology, we believe this strategy
is clinically translatable to extremely premature infants.
As mentioned previously, the AP strategy will require
long-term support (2–4 weeks in humans) and demon-
stration that organs are maturing and protected from
trauma. This corresponds to 10–14 days in the 118 day
lamb model. As such, an in-depth study of lung
development, long-term support, and weaning to a
ventilator and air breathing will be required. A crucial
aspect of lung development will be the airway strategy
during AP support. In our early work, the fetal lambs were
submerged in a warmed “amniotic bath” effectively re-
creating the intrauterine environment.5,7 While appealing
in some regards, there are infection and patient access
issues with this approach. More recently, we have been
intubating the fetal lambs, filling themwith amniotic fluid
or Perflubron and either capping the endotracheal tube or
maintaining 5–8 cmH2O pressure. It is possible to harness
the power of mechanotransduction with this approach and
possibly accelerate lung growth.8,9
Apart from lung development which is crucial during
AP support, other vulnerable premature organs need to be
examined. Brain perfusion, function, and development
are critical to understand. Although the sheep is not a
good model for IVH, brain physiology and evidence of
whitematter injury can be assessed.With a high incidence
of NEC in premature infants, optimal nutrition and
perfusion of the gastrointestinal system warrants investi-
gation. Long term survivors of the AP should be examined
for evidence of retinopathy of prematurity. Lastly, renal
and hepatic function should be addressed.
As a general rule, extracorporeal support is reserved for
infants  34 weeks EGA due to a higher rate of IVH in
extremely premature infants. The authors point out the
feasibility of “preemie ECMO” in infants from 29 to
33 weeks,2 but ELGANs would have prohibitively high
rates of IVH. As such, a critical barrier to clinical
application will be the development of non-thrombogenic
surfaces that will obviate the need for anti-coagula-
tion.10,11 Lastly, clinical application will require a clinical
prognostication tool to select premature infants at the
highest risk for mortality on the first day of life.12
Given recent advances and ongoing work, we believe
that the AP will be used in ELGANs in the next 5 years.
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abstract or references). We ask that the abstracts for these manuscript types do not
exceed 250 words. There is no set limit on images, tables, or references for these types
of manuscripts.
Case Reports
 
Pediatric Pulmonology will review case report manuscripts that present unique,
paradigm-changing, or novel accounts of infantile or childhood disorders. Priority for
selection for publication will be given to the following categories:.
1. Novel therapies and outcomes for cystic fibrosis 
2. Novel disorders or outcomes of ChILD, NEHI, ABCA3 disorders, and surfactant
disorders 
3. Novel congenital malformations 
4. Novel genetic disorders 
5. Novel therapies or outcomes for other disorders
There is not a related format for a case series. Manuscripts of this nature will be treated
as original articles or reviews and will compete with other manuscripts in these
categories. 
Case reports should be concise (a maximum of 1,000 words, not including the abstract
or references), and contain a maximum of two images and/or tables. The
summary/abstract should not exceed 100 words. Case Reports should contain no more
than five (5) references. Authorship of case reports shall be limited to three (3).
Physicians who participated in the care, but did not contribute to the writing of the
manuscript may be listed under acknowledgements. Informed consent must be
documented. Authors should note that most accepted Case Reports will be published
online only, and not in a print edition.
Editorials (Commentaries)
Editors and members of the Editorial Board may make editorial comments on individual
articles or on a group of articles published in the same issue. Editorials (including
pro/con debates) from authors who are not part of the editorial team are also welcome as
submissions to the Journal. These narrowly focused articles should discuss an article
that was recently published, or that is soon to be published. The commentary should
discuss specific issues within a subject area rather than the whole field, while explaining
the implications of the article and putting it in context. Opinions must be factually
based. These types of manuscripts should be limited to 1,500 words (not including the
abstract or references). There is no limitation on the number of tables, images or
references for these types of manuscripts.
Letters to the Editors
We encourage letters that offer criticism of published material in an objective,
constructive, and educational manner conducive to further exchanges. Such letters will
only be considered if they are in reference to an article published within the previous six
months. Letters may also discuss matters of general interest pertaining to the field of
pediatric pulmonology, or may consist of brief reports of truly unique cases. Note that
we do not publish original, previously unpublished data as letters. If appropriate, a copy
will be sent to the author(s) referred to in the letter, so that they may respond. Letters to
the Editor should not exceed 1,000 words (not including the abstract or references), and
may contain a small table or single image. Letters should contain no more than five (5)
references.
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PRIOR TO SUBMITTING
Prior to submitting a manuscript through ScholarOne
(http://mc.manuscriptcentral.com/ppul), prepare the text and images according to the
instructions found below. You may enter and exit the manuscript submission process at
the completion of each step, and you may save an unfinished draft in the system to work
on later. However, once you submit your manuscript though the system, you will not be
able to access it for editing. If you have any questions about this process please contact
us at edsupport@wiley.com (mailto:edsupport@wiley.com)
We recommend all authors familiarize themselves with the International Committee of
Medical Journal Editors: Uniform Requirements for Manuscripts submitted to
Biomedical Journals. Ann Intern Med 1997;126:36-47. The complete text of the
document be found online at www.icmje.org (http://www.icmje.org)
COMPONENTS OF ARTICLES/FILE PREPARATION
Please make note of the following when preparing your submission:
Main Document
All manuscript types must include a title page, abstract, text and references in the Main
Document. Standard, double-spaced manuscript format, in 12 point font is requested.
Number all pages consecutively.
Title page: The title should be brief (no more than 100 characters in length including
spaces) and useful for indexing. All authors’ names with highest academic degree,
affiliation of each, but no position or rank, should be listed. For cooperative studies, the
institution where research was primarily done should be indicated. In a separate
paragraph, specify grants, other financial support received, and the granting institutions
(grant number(s) and contact name(s) should be indicated on the title page). If support
from manufacturers of products used is listed, assurances about the absence of bias by
the sponsor and principal author must be given. Identify meetings, if any, at which the
paper was presented. The name, complete mailing address, telephone number, fax
number, and e-mail address of the person to whom correspondence and reprint requests
are to be sent must be included. Keywords should also be noted on the title page. For
usage as a running head, provide an abbreviated title (maximum 50 characters) on the
bottom of the title page.
Summary/Abstract: In accordance with the structure of the article, with or without
separate headings, outline the objectives, working hypothesis, study design, patient-
subject selection, methodology, results (including numerical findings) and conclusions.
The Summary should not exceed the word counts outlined above. If abbreviations are
used several times, spell out the words followed by the abbreviations in parentheses.
Acknowledgements: Technical assistance, advice, referral of patients, etc. may be
briefly acknowledged at the end of the text under “Acknowledgements.”
Informed Consent: Informed consent statements, if applicable, should be included in
the Methods section.
References/citations: References may be included at the end of your text, or uploaded
as a separate file. Ensure your references are up to date, and include a critical selection
from the world literature. References should be prepared according to CSE (Council of
Science Editors) citation-sequence style. Refer to the Scientific Style and Format: The
CSE Manual for Authors, Editors, and Publishers, 8th edition (University of Chicago
Press). Start the listing on a new page, double-spaced throughout.
Number the references in the sequence in which they first appear in the text, listing each
only once even though it may be cited repeatedly.
When citing a reference in the text, the style advocated by CSE suggests numbers
appear in superscript, and appear before punctuation marks (commas or periods). In the
citation-sequence system, sources are numbered by order of reference so that the first
reference cited in the paper is 1, the second 2, and so on. If the numbers are not in a
continuous sequence, use commas (with no spaces) between numbers. If you have more
than two numbers in a continuous sequence, use the first and last number of the
sequence joined by a hyphen, for example 2,4,6-10.
In the references, list the first ten authors of the cited paper. If there are more than ten
authors, list the first 10 authors followed by 'et al'.
Journals’ names should be shown by their abbreviated title in Index Medicus.
Manuscripts in preparation or submitted for publication are not acceptable references. If
a manuscript “in press” is used as a reference, a copy of it must be provided with your
submission.
Sample references:
Standard journal article 
Landau IL, Morgan W, McCoy KS, Taussig LM. Gender related differences in airway
tone in children. Pediatr Pulmonol 1993;16:31-35.
Book with authors 
Voet D, Voet JG. 1990. Biochemistry. New York: John Wiley & Sons. 1223 p.
Book with editors 
Coutinho A, Kazatch Kine MD, editors. Autoimmunity physiology and disease. New
York. Wiley-Liss; 1994. 459 p.
Chapter from a book 
Hausdorf G. Late effects of anthracycline therapy in childhood: evaluation and current
therapy. In: Bricker JT, Green DM, D'Angio GJ, editors. Cardiac toxicology after
treatment for childhood cancer. New York: Wiley-Liss; 1993. p 73-86.
For a book reference only include the page numbers that have direct bearing on the work
described.
Keywords: On the title page, supply a minimum of 3 to 5 keywords, exclusive of words
in the title of the manuscript. A guide to medical subject heading terms used by PubMed
is available at http://www.nlm.nih.gov/mesh/MBrowser.html
(http://www.nlm.nih.gov/mesh/MBrowser.html)
Abbreviations: Define abbreviations when they first occur in the manuscript and from
there on use only the abbreviation. Whenever standardized abbreviations are available
use those. Use standard symbols with subscripts and superscripts in their proper place.
Drug names: Use generic names. If identification of a brand name is required, insert it
in parentheses together with the manufacturer’s name and address after the first mention
of the generic name.
Eponyms: Eponyms (diseases or biologic entities named for persons) should not be
used when standard descriptive terminology is available. Examples include club cells
(formerly known as Clara cells); and granulomatosis with polyangiitis (formerly known
as Wegener’s granulomatosis). It is permissible to use the eponym in parenthesis at the
first mention of the term in cases in which the eponym is still in common use.
Formatting Specific to Original Research Articles: Divide article into: Title Page,
Summary/Abstract, Introduction, Materials and Methods, Results, Discussion, and
References, starting each section on a new page. All methodology and description of
experimental subjects should be under Materials and Methods; results should not be
included in the Introduction. Please ensure the following appears in the appropriate
section of your manuscript:
a concise introductory statement outlining the specific aims of the study and
providing a discussion of how each aim was fulfilled;
a succinct description of the working hypothesis;
a detailed explanation of assumptions and choices made regarding study design and
methodology;
a description of the reasons for choosing the type and number of experimental
subjects (patients, animals, controls) and individual measurements; if applicable,
information about how and why the numbers may differ from an ideal design (e.g.,
the number required for achieving 90% confidence in eliminating Type II error);
specifics about statistical principles, techniques and calculations employed and, if
applicable, methods for rejecting the null hypothesis;
a concise comparison of the results with those of conflicting or confirmatory studies
in the literature;
a brief summary of the limitations of the scientific methods and results; and
a brief discussion of the implications of the findings for the field and for future
studies.
Tables
Tables should not be included in the Main Document, but submitted as a separate DOC
or RTF file. Number tables with Arabic numbers consecutively and in order of
appearance. Type each table double-spaced on a separate page, captions typed above the
tabular material. Symbols for units should be used only in column headings. Do not use
internal horizontal or vertical lines; place horizontal lines between table caption and
column heading, under column headings, and at the bottom of the table (above the
footnotes if any). Use footnote letters (a, b, c, etc.) in consistent order in each table. All
tables should be referred to in the text. Do not submit tables as photographs and do not
separate legends from tables.
Images
Image files must be submitted in TIF or EPS (with preview) formats. Do not embed
images in the Main Document. Number images with Arabic numbers and refer to each
image in the text. The preferred form is 5 X 7 inches (12.5 X 17.5 cm). Print
reproduction requires files for full color images to be in a CMYK color space.
Please note authors are encouraged to supply color images regardless of whether or not
they are amenable to paying the color reproduction fees. Color images will be published
online, while greyscale versions will appear in print at no charge to the author. See
Author Charges below.
Journal quality reproduction requires grey scale and color files at resolutions yielding
approximately 300 ppi. Bitmapped line art should be submitted at resolutions yielding
600-1200 ppi. These resolutions refer to the output size of the file; if you anticipate that
your images will be enlarged or reduced, resolutions should be adjusted accordingly.
Lettering on images should be of a size and weight appropriate to the content and the
clarity of printing must allow for legibility after reduction to final size. Labeling and
arrows on images must be done professionally. Spelling, abbreviations, and symbols
should precisely correspond to those used in the text. Indicate the stain and
magnification of each photomicrograph. Photographs of recognizable subjects must be
accompanied by signed consent of the subject of publication. Images previously
published must be accompanied by the author’s and publisher’s permission.
Image legends should be brief, and included as a separate DOC file under the heading:
“Image Legends.” When borrowed material is used, the source of the image should be
shown in parentheses after its legend, either by a reference number or in full if not listed
under References.
Online Supporting Information
Additional non-essential material such as text, appendices, tables, images, video, and
soundtrack files may be submitted for posting as supporting information to an article.
The scientific value of such material should be evident. The material should be
submitted simultaneously with the manuscript so that it may undergo peer review. In
naming these files, please note the file names should be preceded by the letter “E.” For
example “E-table 1,“E-image 1,” “E-text,” etc.
Note that supporting online material is not typeset, nor proofread following the review
process, so please ensure the material is accurate and free of typographical errors.
Supporting material should be prepared in the same manner as the print material.
While supporting information does not appear in the print version, a notation is made
that supporting material is available online.
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POLICIES/DISCLOSURE STATEMENTS
We recognize the importance of developing the highest ethical standards and we are
committed to ethical publication practice. For more information on the publisher’s
policies, please see Wiley-Blackwell Guidelines on Publication Ethics and Best
Practices www.wiley.com/bw/publicationethics (http://exchanges.wiley.com/publishing-
ethics_252.html). Of particular importance is the section on Research Misconduct,
which includes data fabrication, falsification, plagiarism, and inappropriate image
manipulation.
Authors who submit to Pediatric Pulmonology should take heed of the following:
Conflict of Interest: Authors must indicate at the time of submission any potential
conflict of interest (particularly of a fiscal nature) that may have a perceived influence
on the results of the research. The existence of such does not automatically preclude
publication. A conflict of interest statement should appear in the Acknowledgment
section. For further information on Conflict of Interest please visit www.icjme.org
(http://www.icmje.org/conflicts-of-interest/)
Experimental and Publication Ethics: Studies involving human subjects must
conform to the guiding principles of the World Medical Association Declaration of
Helsinki (http://www.wma.net/en/30publications/10policies/b3/). Human subjects must
have given informed consent and the study must have been approved by the Committee
on Human Research at the author(s) institution(s) and a statement to this effect must
appear in the Methods section of the submitted article. It is also important to document
in the Methods section that consent has been obtained from older children and
adolescents. Similarly, animal studies must be approved by an Institutional Animal
Research Review Board and a statement to this effect must appear in the Methods
section. In addition, details of anesthesia and euthanasia must appear in the Methods
section.
Plagiarism: It should be noted that Pediatric Pulmonology employs a plagiarism
detection system. By submitting your manuscript to this journal you accept that your
manuscript may be screened for plagiarism against previously published works.
CrossCheck is a multi-publisher initiative to screen published and submitted content for
originality. Pediatric Pulmonology uses iThenticate software to detect instances of
overlapping and similar text in submitted manuscripts. To find out more about
CrossCheck visit http://www.crossref.org/crosscheck.html
(http://www.crossref.org/crosscheck.html).
Prior Publication: Manuscripts submitted to Pediatric Pulmonology may not have been
published in any part or form in another publication of any type, professional or lay,
including electronic publications, the exception being abstracts of no more than 400
words. Any material available via PubMed or other electronic sources is considered to
have been published. When a question arises, the Editor-in-Chief will determine what
constitutes duplicate publication. If duplicate publication is confirmed, the Editor-in-
Chief will initiate a discussion with the sponsoring institution and the authors.
It is the responsibility of submitting authors to inform the Editor-in-Chief of potentially
overlapping or related data either in submitted manuscripts or papers in press, and such
manuscripts should be appended to the submission. If there is significant overlap in data
with previously published articles this should be addressed by the author in the “Authors
Comments” section during the submission process. In particular, giving reasons why the
new submission should be published. The editors reserve the right to determine whether
or not publication is warranted.
For further information on redundant or duplicate publication, please visit
http://www.icmje.org (http://www.icmje.org/recommendations/browse/publishing-and-
editorial-issues/overlapping-publications.html)
Clinical Trials: We endorse the Consolidated Statement of Reporting Trials
(CONSORT Statement) Lancet 2002;357:1191-1194 which may be accessed at
www.consort-statement.org (http://www.consort-statement.org/). In accordance with
ICMJE standards, all clinical trials must be registered with a database that is publicly
accessible such as http://clinicaltrials.gov/ However, other free of charge public
registries are acceptable. For further information, please visit
http://www.icmje.org/about-icmje/faqs/clinical-trials-registration/
(http://www.icmje.org/about-icmje/faqs/clinical-trials-registration/)
PEER REVIEW PROCESS
Upon submission, authors are encouraged to submit names of experts who they deem
appropriate to review their paper. Authors may also indicate persons to whom they do
not wish the manuscript sent for review. In most cases, articles will be reviewed by at
least two authorities as well as the editorial staff to determine validity, significance,
novelty, and potential impact on the field of contents and conclusions. The reviewers
will be selected by the Editor-in-Chief, Associate Editors, and/or Editorial Board
members. The selection will be made on the basis of expertise, impartiality, and equal
distribution among the available experts, regardless of geographic origin of the
manuscript or locations of the reviewers. Authors will be advised within the shortest
possible time whether their paper is accepted, requires major or minor revisions, or is
rejected. All necessary efforts will be made to ensure a timely review process.
Authors should note the time from submission to final decision can be shortened by a
timely return of a revised manuscript when revision has been requested.
The Editor-in-Chief reserves the right to reject any submission deemed not suitable for
the journal after an in-house review.
FAST TRACK REVIEW
If circumstances so warrant, a fast-track review of a paper may be requested in the cover
letter. At the Editor-in-Chief’s discretion, a fast-track review will be undertaken to
expedite manuscripts that deserve rapid review and publication. Expedited peer review
and publication is rare and is reserved for timely presentation of significant data. If fast-
track review is requested in the cover letter, the corresponding author will be informed if
expedited review has been granted or not.
SUBMISSIONS FROM EDITORS AND EDITORIAL BOARD MEMBERS
Pediatric Pulmonology strives to ensure that any submission from the Editor-in-Chief,
Deputy Editor, the Associate Editors, or from a member of the journal’s Editorial Board
receives an objective and unbiased evaluation. This is achieved by assigning any
research article submitted by the Editor-in-Chief, Deputy or Associate Editors to an
impartial referee who can maintain the integrity of the review process. When
appropriate, Pediatric Pulmonology may also utilize the services of Guest Editors who
are familiar with the peer review processes and policies of the journal. Articles
submitted by Editorial Board members undergo a blinded peer review process that is as
stringent as for those authors who are not on the Board. All submitting authors are
automatically blinded to all aspects of the review process.
AUTHOR CHARGES (AuthorCharges)
Should authors wish for manuscript images appear in color in the print edition, color
reproduction fees will be charged to the authors. Current color reproduction fees are
$800 per figure. Authors do, however, have the option of submitting color images for
online publication, and greyscale images for the print edition at no charge, and we
encourage authors to do so. For information on color charges, please contact Production
Editor, at ppulprod @wwiley.com
MANUSCRIPTS ACCEPTED FOR PUBLICATION
The author identified as the formal corresponding author for the paper will receive an
email prompting them to login into Author Services where via the Wiley Author
Licensing Service (WALS) they will be able to complete a license agreement on behalf
of all authors on the paper:
Online Open
OnlineOpen (http://olabout.wiley.com/WileyCDA/Section/id-406241.html) fulfills
RCUK, Wellcome Trust, NIH, and other funder mandates. Authors can use OnlineOpen
to make their article open access and freely available to all on Wiley Online Library.
Wiley also immediately deposit OnlineOpen articles in PubMed Central and PMC
mirror sites. In addition, authors of OnlineOpen articles are permitted to post the final,
published PDF of their article on a website, institutional repository or other free public
server, immediately on publication.
With OnlineOpen, the author, the author's funding agency, or the author's institution
pays a fee to ensure that the article is made open access.
If the OnlineOpen option is selected the corresponding author will have a choice of the
following Creative Commons License Open Access Agreements (OAA):
(http://creativecommons.org/licenses/by-nc-nd/2.0/uk/)Creative Commons Attribution
License OAA (http://creativecommons.org/licenses/by-nc/3.0/)
(http://creativecommons.org/licenses/by-nc-nd/2.0/uk/)
- Creative Commons Attribution Non-Commercial -NoDerivs License OAA
(http://creativecommons.org/licenses/by-nc-nd/2.0/uk/)
If you select the OnlineOpen option and your research is funded by The Wellcome Trust
and members of the Research Councils UK (RCUK) you will be given the opportunity
to publish your article under a CC-BY license supporting you in complying with
Wellcome Trust and Research Councils UK requirements. For more information on this
policy and the Journal’s compliant self-archiving policy please
visit: http://www.wiley.com/go/funderstatement
(http://www.wiley.com/go/funderstatement)
For RCUK and Wellcome Trust authors click on the link below to preview the terms and
conditions of this license:
Creative Commons Attribution License OAA   (http://creativecommons.org/licenses/by-
nc/3.0/)
Note to NIH Grantees: Pursuant to the NIH mandate, Wiley Blackwell will post the
accepted version of contributions authored by NIH grant-holders to PubMed Central
upon acceptance. This accepted version will be made publicly available 12 months after
publication. For further information, see Wiley Blackwell’s NIH Policy Statement.
(http://www.wiley.com/WileyCDA/Section/id-321171.html)
Copyright Transfer Agreement
If the OnlineOpen option is not selected, the corresponding author will be presented
with the copyright transfer agreement (CTA) to sign on behalf of all authors.
To preview the terms and conditions of the open access agreements, or the copyright
transfer agreement, please visit the FAQs hosted on Wiley Author Services. See
http://authorservices.wiley.com/bauthor/faqs_copyright.asp
(http://authorservices.wiley.com/bauthor/faqs_copyright.asp) and
http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html
(http://www.wiley.com/WileyCDA/Section/id-321171.html).
PROOFS
Following acceptance, the corresponding author will be alerted by e-mail to access
galley proofs in web-based proofing system. Corrections should be returned within 48
hours of receipt, as delays in returning galley proofs cause delays in publication.
Alterations should be kept to a minimum. Costs of extensive alterations to the galley
proof will be billed to the authors. All statements in (or omissions from) published
manuscripts are the responsibility of the authors who are asked to carefully review
proofs prior to publication.
REPRINTS
Reprints may be ordered at: https://caesar.sheridan.com/reprints/eorder/order
(https://caesar.sheridan.com/reprints/eorder/order.php?
DBS=A&PUID=10089&IUID=4440&UNDO=1&SERVICE=2&ACCTUID=75)
APPEAL REQUESTS
Authors who wish to request reconsideration of a rejected manuscript should direct their
query to the Editor in Chief, Tom Murphy, murphyeditorppul@hotmail.com
(mailto:murphyeditorppul@hotmail.com) or the PPUL editorial office,
ppuledoffice@wiley.com (ppuledoffice@wiley.com). Requests must include the
manuscript ID and a detailed description of why the authors believe the paper should be
reconsidered.
Appeal requests will be evaluated by the Editor-in-Chief to determine if an appeal will
be permitted. These appeals will be approved on a very limited basis. If the appeal is
allowed, instructions will be provided on how to resubmit your paper. Authors should
not resubmit their rejected paper without prior approval from the Editors and the
Editorial Office. Requests that are sent elsewhere will not be considered.
PRODUCTION QUESTIONS?
Contact Production Editor at ppulprod@wiley.com
(mailto:ppulprod@wiley.comppulprod)
QUESTIONS ABOUT YOUR SUBMISSION?
Contact the PPUL editorial office at ppuledoffice@wiley.com
(ppuledoffice@wiley.com)
CONTACT THE EDITOR-IN-CHIEF
Thomas Murphy, murphyeditorppul@hotmail.com
(mailto:murphyeditorppul@hotmail.com)
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